Results

Gilead Sciences Inc.

06/04/2021 | Press release | Distributed by Public on 06/04/2021 12:34

Kite's Tecartus® Demonstrates High Response Rate in Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia Earning Priority Review Designation